BioNTech SE (NASDAQ:BNTX) Short Interest Update

BioNTech SE (NASDAQ:BNTX) saw a large decline in short interest during the month of June. As of June 15th, there was short interest totalling 2,740,000 shares, a decline of 9.9% from the May 31st total of 3,040,000 shares. Based on an average trading volume of 718,500 shares, the short-interest ratio is currently 3.8 days. Approximately 1.2% of the company’s shares are sold short.

BioNTech Stock Up 1.4 %

NASDAQ BNTX traded up $1.10 during trading hours on Wednesday, hitting $79.86. The company had a trading volume of 594,046 shares, compared to its average volume of 715,782. BioNTech has a fifty-two week low of $78.02 and a fifty-two week high of $125.83. The company has a market capitalization of $18.99 billion, a price-to-earnings ratio of 159.72 and a beta of 0.23. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.38 and a quick ratio of 11.16. The firm’s 50 day moving average is $91.68 and its 200 day moving average is $94.21.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, May 6th. The company reported ($1.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.60). The firm had revenue of $203.69 million during the quarter, compared to analysts’ expectations of $589.96 million. BioNTech had a net margin of 4.01% and a return on equity of 0.55%. Sell-side analysts anticipate that BioNTech will post -2 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $113.00 price target on shares of BioNTech in a report on Wednesday, June 26th. Evercore ISI assumed coverage on BioNTech in a report on Tuesday, May 14th. They issued an “inline” rating and a $100.00 price target for the company. JPMorgan Chase & Co. cut their price target on BioNTech from $99.00 to $90.00 and set an “underweight” rating for the company in a report on Friday, March 22nd. BMO Capital Markets cut their price target on BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a report on Tuesday, May 7th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $171.00 price target on shares of BioNTech in a report on Thursday, March 21st. One research analyst has rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, BioNTech currently has a consensus rating of “Hold” and an average price target of $111.70.

Hedge Funds Weigh In On BioNTech

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BNTX. PNC Financial Services Group Inc. boosted its position in BioNTech by 42.4% in the 3rd quarter. PNC Financial Services Group Inc. now owns 840 shares of the company’s stock valued at $91,000 after buying an additional 250 shares during the last quarter. FMR LLC lifted its position in shares of BioNTech by 4.6% during the third quarter. FMR LLC now owns 237,844 shares of the company’s stock worth $25,839,000 after purchasing an additional 10,422 shares during the last quarter. Invesco Ltd. lifted its position in shares of BioNTech by 7.4% during the third quarter. Invesco Ltd. now owns 84,335 shares of the company’s stock worth $9,162,000 after purchasing an additional 5,800 shares during the last quarter. Federated Hermes Inc. lifted its position in shares of BioNTech by 60.0% during the third quarter. Federated Hermes Inc. now owns 8,000 shares of the company’s stock worth $869,000 after purchasing an additional 3,000 shares during the last quarter. Finally, O Shaughnessy Asset Management LLC lifted its position in shares of BioNTech by 14.7% during the third quarter. O Shaughnessy Asset Management LLC now owns 6,704 shares of the company’s stock worth $728,000 after purchasing an additional 857 shares during the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.